Breast Cancer New Protocol: Eribulin for Breast Cancer Ulas D. Bayraktar, MD 2016-12-12 Study Efficacy Safety J Clin Oncol 2015;33(6):594-601 Kaufman PA Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane http://doi.org/10.1200/JCO.2013.52.4892 Reviewed by Ulas D. Bayraktar, MD on Dec 12, 2016 Share share .ln-icon{fill:#fff;}
